Skip to main content

Table 1 Patient demographics and baseline disease characteristics, safety population

From: Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin

  G-GR 1800 mg/day
(n = 556)
Age (years)  
 Mean (SD) 66.7 (12.9)
 Median 69.0
 Range 18–92
Age category, n (%)  
  < 55 years 89 (16.0)
 55–64 years 109 (19.6)
 65–74 years 195 (35.1)
  ≥ 75 years 163 (29.3)
Sex, n (%)  
 Male 221 (39.7)
 Female 335 (60.3)
Race, n (%)  
 Caucasian 479 (86.2)
 African American 29 (5.2)
 Hispanic 38 (6.8)
 Other 10 (1.8)
Baseline VAS (mm)  
 Mean (SD) 66.1 (56.9)
 Median 64.0
 Range 2–91
Baseline VAS category, n (%)  
  ≤ 20 mm 15 (2.7)
  > 20 mm 531 (95.5)
Baseline BPI Sleep Interference by Pain  
 Mean (SD) 5.1 (2.9)
 Median 5
 Range 0–10